Eli Lilly's Combination Therapy Shows Promise in Treating Psoriasis and Obesity

Indianapolis, Friday, 9 October 2026.
Eli Lilly’s trial combining Taltz and Zepbound significantly reduced inflammatory biomarkers in patients with both psoriasis and obesity, highlighting an integrated approach to immunometabolic health.